Randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 64-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study

By Zerbini C.   Ozturk Z. E.   Grifka J.   Maini M.   Nilganuwong S.   Morales R.   Hupli M.   Shivaprakash M.   Giezek H.    

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 2037-2049

Informa Healthcare

Access to resources Recommend Favorite

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder*

By Liebowitz Michael R.   Manley Amy L.   Padmanabhan Sudharshan K.   Ganguly Rita   Tummala Raj   Tourian Karen A.  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1877-1890

Informa Healthcare

Access to resources Recommend Favorite

Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia

By Bays Harold   Sapre Aditi   Taggart William   Liu Ji   Capece Rachel   Tershakovec Andrew  

Current Medical Research and Opinion, Vol. 24, Iss. 10, 2008-10 ,pp. : 2953-2966

Informa Healthcare

Access to resources Recommend Favorite

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

By Mahableshwarkar Atul R.   Jacobsen Paula L.   Chen Yinzhong  

Current Medical Research and Opinion, Vol. 29, Iss. 3, 2013-03 ,pp. : 217-226

Informa Healthcare

Access to resources Recommend Favorite